Algernon Pharmaceuticals provides update on Phase 2B/3 study as they enroll 50th patient

Algernon Pharmaceuticals provides update on Phase 2B/3 study as they enroll 50th patient

 

Algernon Pharmaceutical (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with news the company has now enrolled a third of their patients in the Phase 2B/3 study of their repurposed drug Ifenprodil.

Moreau discusses hitting that mark and also discusses the parameters of that study and whether they plan on releasing early data.

Share via
Copy link
Powered by Social Snap